BCAL Diagnostics Limited logo

BCAL Diagnostics Limited (BDX)

Market Closed
ASX ASX
33.71M Market Cap
- P/E Ratio
0% Div Yield
321,077 Volume
- Eps

Summary

BDX closed Friday higher, an increase of 4.59% from Thursday's close, completing a monthly increase of 0%. Over the past 12 months, BDX stock gained 0%.
BDX is not paying dividends to its shareholders.
The last earnings report, released on Nov 21, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on ASX (AUD).
Want to track BDX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

BCAL Diagnostics Limited (BDX) FAQ

On which exchange is it traded?

BCAL Diagnostics Limited is listed on ASX.

What is its stock symbol?

The ticker symbol is BDX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 33.71M.

Has BCAL Diagnostics Limited ever had a stock split?

No, there has never been a stock split.

BCAL Diagnostics Limited Profile

Diagnostics & Research Industry
Healthcare Sector
- CEO
ASX Exchange
AU0000160921 ISIN
Australia Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

BCAL Diagnostics Limited is a forefront company in the field of healthcare, specializing in screening and diagnostics with a pivotal focus on breast cancer detection. Established in 2010 and based out of Sydney, Australia, the company has dedicated itself to pioneering advancements in medical diagnostics. It aims to revolutionize the existing methods of breast cancer detection by introducing a non-invasive blood test, ensuring a safer and more accessible approach for patients worldwide. The inventiveness of BCAL extends into its research and development, striving towards innovations that promise to enhance breast cancer prevention, screening, and ongoing patient monitoring.

Products and Services

  • BCAL Test

The flagship product from BCAL Diagnostics Limited, the BCAL Test, stands out as a groundbreaking approach in the early detection of breast cancer. This lipid biomarker blood test is designed to offer a non-invasive, efficient, and reliable method for screening. Unlike traditional procedures that often require physical examinations or imaging, the BCAL Test requires only a blood sample from the patient. This can substantially reduce discomfort and increase the feasibility of regular screening, particularly for those at high risk or with dense breast tissue where traditional methods may be less effective. The test works by identifying a specific 'fingerprint' of lipid biomarkers in a patient's blood plasma, which indicates the presence of breast cancer cells, opening a new frontier in cancer diagnostics.

  • In Vitro Diagnostic Test (IVD)

BCAL Diagnostics extends its innovative portfolio with the development of an in vitro diagnostic test (IVD). This diagnostic tool confirms the presence of breast cancer by analyzing a patient's blood plasma to detect a unique configuration of lipid biomarkers. The IVD represents a significant step forward in personalized medicine, allowing for the diagnosis of breast cancer with greater accuracy and specificity. The test not only plays a critical role in the initial detection of breast cancer but also offers potential applications in monitoring the disease's progression and the effectiveness of treatment, contributing profoundly to the overarching goal of improving patient outcomes and survival rates.

Contact Information

Address: 50 Clarence Street
Phone: 61 2 9078 7671